What Is an Independent Pharmacy Worth? EBITDA Multiples Explained
Independent pharmacies sell for 3x–5.5x EBITDA depending on prescription volume, specialty services, payer mix, and compliance history. Here is what moves the needle.
Independent pharmacy valuations in the lower middle market typically range from 3x to 5.5x EBITDA, with prescription file strength, specialty or compounding revenue, and clean DEA compliance driving the upper end. Buyers price in PBM reimbursement risk, DIR fee exposure, and staff retention. Inventory is generally priced separately at cost, and earnouts tied to patient file retention are common in structured deals.
Pharmacy EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or High-Risk | $80K–$200K | 2.5x–3.0x | Declining script volume, heavy PBM dependency, DIR fee exposure, or compliance issues. Buyers require significant price concessions and earnout protection. |
| Stable Independent | $200K–$400K | 3.0x–4.0x | Established patient base with steady refill rates, clean compliance record, but limited specialty revenue and owner-dependent operations. |
| Strong Independent with Niche Services | $400K–$600K | 4.0x–4.75x | Compounding, LTC, or specialty contracts adding margin diversity. Licensed pharmacist staff willing to stay post-close. Recurring institutional revenue. |
| Premium Specialty or LTC Platform | $600K–$900K+ | 4.75x–5.5x | Documented LTC or hospice contracts, strong compounding revenue, transferable systems, and a patient base with low churn command top-tier pricing. |
What Drives Pharmacy Multiples
Prescription File Quality
High impactActive patient count, 30-day refill rates, and top drug category mix directly determine prescription file value, often the largest asset in the transaction.
Specialty and Compounding Revenue
High impactPharmacies with compounding or specialty dispensing reduce PBM dependency, generate higher margins, and command meaningfully higher EBITDA multiples from strategic buyers.
PBM Contract and DIR Fee Exposure
High impactHeavy reliance on low-margin generics with high DIR fee clawbacks compresses reported EBITDA and signals ongoing margin risk that buyers discount aggressively.
DEA and Regulatory Compliance History
Medium impactClean DEA registration, state board standing, and no audit findings from CMS or PBMs are baseline requirements. Any violations reduce buyer pool and compress multiples.
Staff Retention and Pharmacist Continuity
Medium impactA licensed pharmacist willing to remain post-close significantly reduces transition risk. Owner-only operations with no backup pharmacist are a material valuation discount.
Recent Market Trends
PBM reimbursement compression and rising DIR fees have pushed more independent pharmacy owners to accelerate exit timelines, increasing deal flow in 2023–2024. PE-backed platforms are selectively acquiring compounding and LTC pharmacies at premium multiples, while standard retail pharmacies face tighter buyer scrutiny. SBA 7(a) financing remains the dominant deal structure for individual buyers, with seller carry of 10–20% increasingly required to close valuation gaps.
Sample Pharmacy Transactions
Single-location retail pharmacy in the Southeast with strong 30-day refill rates, clean compliance, and a licensed staff pharmacist retained post-close.
$320,000
EBITDA
3.75x
Multiple
$1,200,000
Price
Independent compounding pharmacy with institutional contracts and documented LTC facility relationships, acquired by a regional pharmacy chain expanding specialty services.
$580,000
EBITDA
5.0x
Multiple
$2,900,000
Price
Owner-operated retail pharmacy with declining script volume and heavy PBM exposure, sold via asset purchase with earnout tied to 12-month patient retention.
$160,000
EBITDA
2.75x
Multiple
$440,000
Price
EBITDA Valuation Estimator
Get your Pharmacy business value range instantly
Industry: Pharmacy · Multiples based on 3.0x–4.0x (Stable Independent)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
How is an independent pharmacy valued beyond EBITDA?
Prescription file value, inventory at cost, and real estate or lease terms are priced separately. The prescription file is often the largest asset and is valued on active patient count and refill rates.
Do PBM contracts transfer to a new pharmacy owner?
Not automatically. Change-of-ownership provisions in PBM contracts must be reviewed carefully. Some networks require reapplication and credentialing, which can delay closing and create revenue gap risk.
Can I use an SBA loan to buy an independent pharmacy?
Yes. Pharmacies are SBA 7(a) eligible. Most deals use SBA financing with a 10–15% buyer down payment, seller carry of 10–20%, and earnouts tied to prescription volume retention over 12–24 months.
What kills pharmacy deal value most often?
Declining script volume, high DIR fee exposure, DEA or state board compliance issues, and an owner-only operation with no licensed backup pharmacist are the most common valuation killers buyers cite.
More Pharmacy Guides
Find Pharmacy businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required